Background Eczema is a common and chronic, relapsing, inflammatory skin disorder. It
seriously impacts quality of life and economic outcomes, especially for those with moderate …

Currently, there are a few detailed guidelines on the overall management of children and
adolescents with moderate-severe atopic dermatitis. AD​​ is a complex disease presenting …

Background Conventional systemic drugs are used to treat children and young people
(CYP) with severe atopic dermatitis (AD) worldwide, but no robust randomized controlled …

Atopic dermatitis (AD) is a chronic inflammatory, relapsing disease of the skin, characterized
by intense pruritus, maculopapular or vesicular erythematous lesions and scaling …

Purpose: For individuals with atopic dermatitis (AD), interpreting scientific papers that
present clinical outcomes including the Eczema Area and Severity Index (EASI) and …

Importance Dupilumab, methotrexate (MTX), and cyclosporine A (CsA) are valuable
treatment options for pediatric patients with refractory moderate to severe atopic dermatitis …

Patients with atopic dermatitis (AD) who do not adequately respond to topical therapy and
phototherapy often need systemic immunomodulatory treatment to control their symptoms …

This entirely revised edition of the successful work presents the state of the art in clinics,
research and practical management of atopic dermatitis-eczema. The wide variability in …

The last 10 years has seen incredible advances in our knowledge of the epidemiology,
pathogenesis and treatment of eczema. This editorial introduces a British Journal of …

Among special therapeutic options, anti-inflammatory treatment using topical
glucocorticosteroids (TCS) or topical calcineurin inhibitors (TCI) are core elements …